ASMB stock forecast
Our latest prediction for Assembly Biosciences, Inc.'s stock price was made on the Aug. 7, 2020 when the stock price was at 21.85$.
In the short term (2weeks), ASMB's stock price should underperform the market by -2.13%. During that period the price should oscillate between -10.36% and +9.96%.
In the medium term (3months), ASMB's stock price should underperform the market by -7.27%. During that period the price should oscillate between -37.52% and +24.39%.Get email alerts
Create a solid portfolio with ASMB
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
At the moment the company generates 52M USD in revenues.
On its last earning announcement, the company reported a loss of -2.50$ per share.
The book value per share is 3.50$
Three months stock forecastAug. 7, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|